Technologies

We believe in a world in which treatments for blinding ocular diseases are a reality for all.

Gene Therapy

Gene therapy uses a delivery vehicle, referred to as a vector, to introduce a gene encoding a therapeutic protein into cells to replace the defective or missing mutated gene responsible for the patients’ disease.

Yet, unlike traditional, monogenic gene therapies which target a specific gene, our AAV-based gene therapy products work independently of the causative gene mutation to restore physiological mechanisms in the retina and preserve vision.

SPVN06

SparingVision’s lead product, SPVN06, is a breakthrough gene therapy approach targeting Inherited Retinal Diseases (IRDs).

Learn More
SPVN20/30

SparingVision’s second product, SPVN20, is a pioneering gene therapy product obtained through the acquisition of Gamut Therapeutics.

Learn More